Clinical Trials Logo

Clinical Trial Summary

This is a multicenter, randomized, double-blind study to evaluate the efficacy and safety of TRM-201 (rofecoxib) versus Placebo in the treatment of patients with hemophilic arthropathy (HA) over a 12-week period (Part I) that is followed by a year-long (52 week) open-label extension (Part II) to further evaluate the safety and maintenance of efficacy of TRM-201.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04684511
Study type Interventional
Source Tremeau Pharmceuticals, Inc.
Contact
Status Terminated
Phase Phase 3
Start date June 2, 2021
Completion date September 28, 2022

See also
  Status Clinical Trial Phase
Completed NCT01232634 - Validation of Ultrasound as a Diagnostic Tool for Assessment of Hemophilic Arthropathy of Knees and Ankles Phase 2
Completed NCT02994147 - A Proof-of-Concept Study of AC-201 Controlled-Release Tablet (CR Tablet) in Patients With Hemophilic Arthropathy Phase 2
Completed NCT02601170 - Platelet-Rich Plasma Intra-Articular Injection in Treating Hemophilic Arthropathy N/A
Recruiting NCT05517070 - Vitamin D Deficiency and Body Composition in the Patients With Hemophilia
Completed NCT04297696 - The Effects of Exercises on Gait in Hemophilic Individuals N/A
Completed NCT04535180 - Sarcopenia and Osteoporosis in the Patients With Hemophilia
Terminated NCT02569359 - Efficacy and Safety of Shea Nut Oil in Hemophilic Arthropathy N/A